Menu

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics

Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies

Jun 13, 2019
Gyros Protein Technologies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new host cell protein (HCP) kit for automated impurity analysis of biotherapeutics expressed in E. coli systems. The new kit is optimized for use in Gyrolab® systems and has been developed as part of a licensing and supply agreement with Cygnus Technologies (part of Maravai LifeSciences), incorporating their industry standard E. coli HCP antibodies and other reagents.

 Gyrolab E. coli HCP Kit quantifies HCP impurities from E. coli expression systems used in the production of biotherapeutics, a critical step in ensuring the efficacy and safety of the drug molecule. As the latest addition to the growing menu of ready-to-use kits, the new kit is a key tool for the automated analysis of bioprocess samples, offering further support to customers working in biotherapeutics process development and manufacturing.

 Gyros Protein Technologies has established expertise in bioprocess development, through its Gyrolab platforms and ready-to-use kits for CHO-HCP, Protein A impurity analyses, and IgG titer determinations. Gyrolab systems provide automated immunoassays for impurities such as HCPs, with a fast turn-around time, broad dynamic ranges and high reproducibility, making it an ideal technology to support all phases of biotherapeutic bioprocess development and production.

October 2019

Brain Fog

Air Pollution May Cause Cognitive Decline

Marketplace

Sponsored Product Updates

Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
·        Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting· The MODA-ES™ Platform was implemented at Nephron in an aggressive nine-month time frame, improving operational efficiency and enabling a significant product line expansion·        Full results of the collaboration will be co-presented by Lonza and Nephron at the 2019 ISPE Annual Meeting & Expo in Las Vegas, Nevada
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Vladimir Senyukov, Director of BioAnalytical Development at Precision Biosciences, talks about investigating T-cell cytokine production using single cell proteomics in order to unlock the therapeutic potential of allogenic CAR-T cells.
Zymo Research launches new RNA-Seq library prep kit
Zymo Research launches new RNA-Seq library prep kit
Zymo Research is excited to announce the fastest and easiest total RNA-Seq library prep kit that allows users to go from sample to sequencer in a single day!